Drug Ther Bull. 2016 Jun;54(6):66-9. doi: 10.1136/dtb.2016.6.0405.
▼ Sacubitril valsartan (Entresto-Novartis) is a new oral drug licensed for the treatment of symptomatic chronic heart failure in adults with reduced ejection fraction.(1) It is described as an angiotensin receptor neprilysin inhibitor and contains the neprilysin inhibitor, sacubitril and the angiotensin II receptor antagonist, valsartan.(1-3) Here, we review the evidence for sacubitril valsartan and consider its place in the management of heart failure.
沙库巴曲缬沙坦（诺华公司的恩格列净）是一种新型口服药物，已获许可用于治疗射血分数降低的成年患者的症状性慢性心力衰竭。（1）它被描述为一种血管紧张素受体脑啡肽酶抑制剂，含有脑啡肽酶抑制剂沙库巴曲和血管紧张素II受体拮抗剂缬沙坦。（1-3）在此，我们回顾了沙库巴曲缬沙坦的证据，并探讨其在心力衰竭管理中的地位。
